Over ten years of advanced research and development, American Gene Technologies™ (AGT), has built a broad, robust gene delivery platform that accelerates the development of a wide variety of drug candidates. This platform allows AGT to pursue exciting clinical “cures” in large and orphan indications to complex diseases. AGT has an extensive and growing patent portfolio protecting its lentiviral vector and proprietary process for generating autologous cell products that treat HIV as well as its methods and Composition for the Activation of Gamma Delta T cells to kill solid cancer tumors.
Using its platform and patented methods, AGT has built a rich product pipeline of genetic therapies for patients suffering from infectious disease, monogenic disorders, and cancer.
Its three lead programs for HIV, Liver Cancer, and Phenylketonuria (PKU) are well into the laboratory phase and scheduled to move into the clinic. The Company is expecting to begin clinical trials this year for an HIV cure based on a successful pre-IND meetings with the FDA. Read more about each lead candidate:
- Granted 2 USPTO patents to protect its lentiviral vector and proprietary process for generating autologous cell products for treating HIV (“HIV Pre-Immunization and Therapy”)
- Signed Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy
- Former scientific advisor, Robert R. Redfield, M.D., was appointed Director of the Centers for Disease Control and Prevention (CDC)
- Completed process development for the AGT103-T automated cell manufacturing protocol; the GMP vector for the HIV cure program was completed.
- Selected University of Maryland, Baltimore (UMB) as the new clinical site for its non-IND study, AGT-CS168, to collect sample venous blood specimens from HIV positive individuals